key: cord-0792819-alrxnzae
authors: Evans, Paul C; Ed Rainger, G; Mason, Justin C; Guzik, Tomasz J; Osto, Elena; Stamataki, Zania; Neil, Desley; Hoefer, Imo E; Fragiadaki, Maria; Waltenberger, Johannes; Weber, Christian; Bochaton-Piallat, Marie-Luce; Bäck, Magnus
title: Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science
date: 2020-08-04
journal: Cardiovasc Res
DOI: 10.1093/cvr/cvaa230
sha: 51632d197bc07acb8f3055f429e1d9b35512aa25
doc_id: 792819
cord_uid: alrxnzae

The COVID-19 pandemic is an unprecedented healthcare emergency causing mortality and illness across the world. Although primarily affecting the lungs, the SARS-CoV-2 virus also affects the cardiovascular system. In addition to cardiac effects, e.g. myocarditis, arrhythmias, and myocardial damage, the vasculature is affected in COVID-19, both directly by the SARS-CoV-2 virus, and indirectly as a result of a systemic inflammatory cytokine storm. This includes the role of the vascular endothelium in the recruitment of inflammatory leucocytes where they contribute to tissue damage and cytokine release, which are key drivers of acute respiratory distress syndrome (ARDS), in disseminated intravascular coagulation, and cardiovascular complications in COVID-19. There is also evidence linking endothelial cells (ECs) to SARS-CoV-2 infection including: (i) the expression and function of its receptor angiotensin-converting enzyme 2 (ACE2) in the vasculature; (ii) the prevalence of a Kawasaki disease-like syndrome (vasculitis) in COVID-19; and (iii) evidence of EC infection with SARS-CoV-2 in patients with fatal COVID-19. Here, the Working Group on Atherosclerosis and Vascular Biology together with the Council of Basic Cardiovascular Science of the European Society of Cardiology provide a Position Statement on the importance of the endothelium in the underlying pathophysiology behind the clinical presentation in COVID-19 and identify key questions for future research to address. We propose that endothelial biomarkers and tests of function (e.g. flow-mediated dilatation) should be evaluated for their usefulness in the risk stratification of COVID-19 patients. A better understanding of the effects of SARS-CoV-2 on endothelial biology in both the micro- and macrovasculature is required, and endothelial function testing should be considered in the follow-up of convalescent COVID-19 patients for early detection of long-term cardiovascular complications.

Coronavirus Disease 2019 is caused by a single strand RNA virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that likely crossed from bats to humans following a gain-of-function mutation in the spike protein that allows infection of human cells 1 . Though primarily known as a disease affecting the respiratory system, cardiovascular complications are common in COVID-19 2 3 . These include myocarditis and myocardial injury that may lead to heart failure. Myocardial infarction (MI) and Takotsubo syndrome has been reported in patients with COVID-19 4 5 . An increase in troponin levels in COVID-19 is associated with more severe disease and mortality, underlining that myocardial injury as a prognostic factor 6 . Increased levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) is also an independent predictor of in-hospital death in COVID- 19 patients, but at lower levels than in heart failure 7 , suggesting that relatively mild alteration in cardiac function may critically determine outcome in COVID- 19 . In addition, arrhythmias are remarkably prevalent among patients with COVID-19 with an incidence of 16.7% reported in a Chinese cohort 8 . Cardiomyocytes are known to express angiotensin converting enzyme 2 (ACE2) 9 , which is the receptor for SARS-CoV-2, however direct evidence of cardiomyocyte infection is lacking.

In addition, underlying cardiovascular disease may aggravate the clinical course of disease in COVID-19. Meta-analysis of data from Chinese cohorts revealed that fatality rates in hospitalised patients with COVID-19 were elevated in those with cardiovascular disease (10.5%), diabetes (7.3%) or hypertension (6%) compared to patients without comorbidities (0.9%) 10 . Cohorts of patients from Italy and U.S. 11 also show that hypertension, diabetes and obesity are common co-morbidities.

Increased D-dimer (fibrin degradation product) levels is a marker of adverse COVID-19 outcomes 12 and disseminated intravascular coagulation with significant risk of venous thromboembolism (VTE) and ischaemic stroke has been reported 13 14 15 . A study of systematic duplex ultrasound in 26 severe COVID-19 patients reported a cumulative VTE incidence of 69% despite anticoagulation treatment 16 . Ischemic stroke has been linked to COVID-19 progression because it had a higher incidence in patients with severe disease compared to those with milder symptoms 17 . A report of six ischaemic stroke cases from the UK revealed an association with elevated D-dimers, systemic inflammatory changes, and anti-phospholipid antibodies, which are indicative of hypercoagulability 18 . However, caution should be exercised in attributing stroke to viral infection since there were several potential confounding factors including hypertension and atrial fibrillation, which enhance stroke risk.

We refer the reader to Guzik et al 19 for a more complete description of cardiac effects in COVID-19. The aim of this Position Statement from the Working Group on Atherosclerosis and Vascular Biology together with the Council of Basic Cardiovascular Science of the European Society of Cardiology is to draw attention to the importance of the endothelium in COVID-19 and to encourage research on endothelial dysfunction and biomarkers to tackle the COVID-19 pandemic and its potential long-term cardiovascular complications.

The characteristic hyperinflammatory and pro-coagulatory state of COVID-19 implies a critical role of the endothelium, both as an effector contributing to inflammation and thrombosis, and as a target organ, whose dysfunction may contribute to poor outcome 20 . Of particular note, there is also evidence of SARS-CoV-2 infection of vascular ECs [21] [22] [23] [24] .

The vascular endothelium forms a critical interface between the circulatory system and underlying tissues and has vital and ubiquitous roles in cardiovascular homeostasis by regulating the transport of cells, nutrients and metabolites between the circulation and underlying tissues 25 . Several risk factors for cardiovascular disease including diabetes, obesity, dyslipidemia, smoking and disturbed blood flow can induce EC dysfunction which is characterised by a spectrum of phenotypes 262728 . These include loss of integrity (e.g. via apoptosis) which is associated with increased permeability; induction of cytokines and adhesion molecules to capture inflammatory cells from the circulation; metabolic changes; a pro-thrombotic phenotype and dedifferentiation 2926 . This is exemplified in multiple studies showing that quantitation of EC function provides a useful marker for early disease detection and stratification of patients with cardiovascular disease 3031 . The European Society of Cardiology recently reviewed this subject and called for further investigation of EC pathophysiological states, optimisation and standardisation of methodologies for clinical measurement of EC function as well as larger clinical trials to establish reference values and assess clinical utility 25 .

Emerging evidence indicates that EC dysfunction is a central feature of COVID-19. This is evidenced by the critical role of vascular endothelium in inflammation, which is the key driver of cytokine dysregulation in ARDS as well as multiple cardiovascular pathologies. Additionally, the pro-thrombotic phenotype and disseminated intravascular coagulation observed in COVID-19 reflect dysfunction of EC, which enhances thrombosis by reduced integrity leading to exposure of pro-thrombotic sub-endothelial material, capture of platelets and regulation of clotting cascades, thrombin activation and fibrin production 32 .

There are several other lines of evidence that substantiate the role of endothelium in COVID-19 ( Figure 1 ):

(1) Recruitment of leukocytes, immune response and tissue injury. Leukocytes play an important role in the pathogenesis of SARS-CoV-2. The importance of the leukocyte-EC axis is exemplified by the observations that patients with severe disease demonstrate a marked increase in blood neutrophils which is associated with lymphopenia, with both CD4 + T cells and CD8 + T cells being lower in severe compared to moderate cases 33 . Moreover, histological examination of a severe case, who died of SARS-CoV-2 demonstrated lung interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes 34 . Through the systemic inflammatory response in COVID-19, referred to as cytokine storm, or cytokine release syndrome, the endothelium will be directly exposed to pro-inflammatory cytokines that initiate transcriptional programmes, that induce adhesion molecules and chemokines driving leukocyte recruitment and inflammation 35 . This process can also lead to EC death that contributes to increased vascular permeability and end-organ damage. Through an amplification loop of the inflammatory response, the endothelium may constitute a significant source of proinflammatory cytokines e.g. interleukin (IL)-1 and IL-6, that characterize the cytokine storm in COVID-19 36 37 . Since the process of lymphocyte trafficking in chronic inflammatory and auto-immune diseases is a major therapeutic target, it is possible that anti-inflammatory therapies developed for these conditions could be repurposed to treat SARS-CoV-2 infection.

It is uncertain whether modulating EC function during the inflammatory response to SARS-CoV-2 would be beneficial, with the dilemma that antiinflammatory agents might be counterproductive and compromise the immune response against the virus. However, in mouse models of pathogenic influenza and respiratory syncytial virus (RSV) infection, where there is evidence that the EC orchestrate a CD8 + T cell-mediated cytokine storm, agonists of the S1P 1 receptor are effective in improving survival [38] [39] [40] . It is also noteworthy that adiponectin is protective in models of sepsis and ARDS through suppression of EC activation 41 . Such observations raise the question of whether the immune response itself may contribute to chronic inflammatory process in severe SARS-CoV-2 infection. The immunology of SARS-CoV-2 infection has recently been comprehensively reviewed by Vabret et al 42 who noted that in SARS-CoV-1 patients survival was associated with immunity skewed towards a CD8 cytotoxic response 43 . Indeed, there is evidence that expansion of virus specific CD4 T cells and a robust Th2 response (including increases in plasma IL-4, IL-5 and IL-10) are associated with death in SARS-CoV-1 44 . Whether this is the case in SARS-Cov-2 remains to be established. It does however appear that the adaptive immune response is an important arbiter of outcomes in SARS-CoV-2, as there is a reported association between plasma IgA titers and severity of disease 45 . It is possible that in SARS-CoV-2, antibody-dependent enhancement (ADE) of inflammation plays a role in EC activation and pathology. In this phenomenon non-neutralising antibodies facilitate Fcmediated uptake of virus into macrophages, resulting in their activation and liberation of inflammatory cytokines, leading to the secondary recruitment of inflammatory leukocytes by local EC. The phenomenon of ADE is readily demonstrable in a number of experimental models of SARS infection but there is currently no evidence that ADE contributes to pathology in SARS-Cov-2 42 . Since the process of EC dependent leukocyte trafficking in chronic inflammatory and auto-immune diseases is a major therapeutic target, it is possible that anti-inflammatory therapies developed for these conditions could be repurposed to treat SARS-CoV-2 infection. Indeed, the recent success of low dose dexamethasone in the RECOVERY-trial, and its adoption as a front line therapy for SARS-CoV-2 in the UK, is an exemplar of the utility of such an approach (see below).

(2) Endothelium and thrombosis When dysfunctional, the thrombotic and coagulant properties of the endothelium change 35 . In particular, a decreased anti-aggregatory prostacyclin production from EC and an increased pro-aggregatory thromboxane synthesis from activated platelets 46 may skew the homeostatic situation towards a pro-thrombotic and pro-inflammatory phenotype. Interestingly, under some inflammatory conditions EC express adhesion receptors such as von Willebrand Factor on their surface. Both in vitro and in vivo these conditions have been demonstrated to support the recruitment and activation of platelets to intact endothelial monolayers 47 . This in turn can lead to the platelet dependent secondary recruitment of circulating leukocytes, either by leukocyte interactions with platelets adherent to EC 48 , by the recruitment of circulating heterotypic aggregates of platelets and leukocytes 49 , or by the transfer of platelet borne receptors such as GPIb to the leukocyte membrane by platelet derived microvesicles 50 . It is reasonable to assume that such tri-cellular aggregates (EC-platelet-leukocyte) on the walls of smaller vessel would be sufficient to cause loss of microvascular perfusion in the lungs and other organs. Indeed, compromise of myocardial perfusion could play a role in the elevated levels of troponin evident in many SARS-CoV-2 patients. Intravascular thrombosis and coagulation in addition may further damage the endothelium and contribute to endothelial inflammation and dysfunction 35 . In some patients with COVID-19 severe micro-vascular endothelial injury directly mediated by activation of the alternative and lectin complement pathways has been demonstrated and associated with a pro-coagulant state 51 . It remains however to be established if anti-coagulation or platelet inhibition in COVID-19 improves endothelial function, and if dampened endothelial inflammation would attenuate the procoagulant state in COVID-19.

(3) ACE2 expression and function in endothelium. ACE2 is intimately linked to cardiovascular physiology as part of the reninangiotensin-aldosterone system (RAAS), which controls blood pressure by altering vascular tone and function. The related molecule ACE converts angiotensin (Ang) I to Ang II, which promotes vasoconstriction, hypertension and vascular inflammation. Because of these properties, anti-hypertensive drugs have been developed to reduce the production (ACE inhibitors, ACE-i) or downstream effects (Ang II receptor blockers, ARBs) of Ang II. The effects of ACE are opposed by ACE2, which converts Ang II into Ang 1-7 molecules thereby promoting vasodilatation and reducing hypertension 52 . Since ACE2 is expressed in cells of the cardiovascular system 53 , there has been considerable interest in the hypothesis that this class of anti-hypertensive drugs may increase the risk of SARS-CoV-2 infection by increasing the expression of ACE2 in vascular cells 54 . However, population-based studies revealed that ACE inhibitors and ARBs do not enhance the risk of COVID-19 or disease severity 55 56 and the European Society of Cardiology and other learned societies recommend that patients should continue with their usual anti-hypertensive medications during the pandemic (https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang).

The spike (S) protein of the coronaviruses mediates viral entry into target cells. Entry depends on physical interactions of the surface unit, S1, of the S protein to a host cell receptor, which facilitates viral attachment to the surface of the target cells. SARS-CoV-2 engages ACE2 as the primary receptor 57, 58 59 and hence it is plausible that COVID-19 may cause reduced bioavailability of ACE2 due to endosomal/lysosomal processing 52 . Treatment of COVID-19 patients with recombinant ACE2 is currently under clinical trial because this may act as a decoy receptor 60 , hence limiting viral entry. It is notable recombinant ACE2 treatment may have additional beneficial effects, by increasing its bioavailability at the endothelial surface. The S2 domain of the S protein facilitates membrane fusion, which requires conformational flexibility, achieved by proteolytic cleavages. The cleavage event employs the cellular transmembrane protease, serine 2 (TMPRSS2), and has profound implications on virulence. A TMPRSS2 inhibitor, approved for clinical use, was shown to block entry and might constitute a treatment option 57 . It has been reported that TMPRSS2 expression is below detection in microvascular endothelial cells 61 and only upregulated in endothelial cells actively undergoing angiogenic or tubulogenic responses. Further studies are needed to better understand the physiological expression and function of TMPRSS2 in adult endothelial cells. However, the expression of TMPRSS2 alone may not be predictive of its function since serine proteases, such as TMPRSS2, are regulated by nitrosylation 62 . Therefore it is plausible that eNOS activity and subsequent production of NO may influence viral infection of EC by altering TMPRSS2 activity. Taken together the S protein mediates entry by connecting the virus to the plasma membrane, and by catalysing subsequent virus-cell membrane fusions.

(4) SARS-CoV-2-induced endothelitis. In addition to the respiratory tract, ARS-CoV-2 viral load is detected in kidneys, liver, heart, and brain 63 , which are all highly vascularized tissues. Indeed, Monteil et al provided an early indication of SARS-CoV-2 tropism for vascularized tissues by demonstrating that this virus can infect human blood vessel and kidney organoids via ACE2 59 . It was suggested by Varga et al by electron microscopy and histology that SARS-CoV-2 can be detected in EC of the kidney (glomerular capillaries), small bowel, lung and myocardium 21 , but these data were recently disputed 64 . Ackerman et al 22 have shown abnormalities within the pulmonary microvasculature with congestion and micro-thrombi similar to Menter et al 23 , and by electron microscopy there is endothelial injury and congestion with cell fragments and degenerate organelles in the lumen. Scanning electron microscopy of corrosion casts shows microvasculature of larger diameter with an irregular surface, which may be due to endothelial injury and/or platelet aggregates/fibrin. Intriguingly there was also evidence of intussusceptive angiogenesis and the authors speculate that this feature may distinguish the pulmonary pathobiology of COVID-19 from other viral infections. SARS-CoV-2 has also been detected in skin EC 24 and circulating endothelial cells are elevated in patients admitted to hospital with COVID-19 65 .

Taken together, these studies point to endothelial SARS-CoV-2-infection as a possible direct trigger of endothelial adverse effects in COVID-19. Indeed, SARS-CoV-2 infected endothelium has been associated with EC apoptosis, suggesting a possible mechanism though which the endothelium may become dysfunctional in COVID-19 21 (5) Pericytes. Pericytes are multifunctional mural cells of the microvasculature and are essential for the maintenance of the endothelium integrity 70 . Studies suggest that they are involved in COVID-19-related vasculopathy. Recent single-cell or single-nucleus RNA sequencing analyses have shown that ACE2 is highly expressed in pericytes of various organs, such as the heart, both in mouse and man 71 72 . In alveolar capillary of SARS-CoV-2 infected lung, pericytes are markedly decreased, likely through apoptosis 73 . In a genetically modified mouse model with pericyte deficiency (pdgf-b ret/ret mouse 74 ) induced by deletion of the PDGF-B retention motif, loss of pericytes induced thrombogenic reactions in ECs 72 . Therefore, pericytes by acting as direct target for SARS-CoV-2 infection, could play a crucial role in microvascular dysfunction and coagulopathy. It is suggested that a permeable endothelial barrier as observed in hypertension, diabetes and obesity, which are comorbidity factors in severe cases of COVID-19, allows the virus to reach the pericytes 72 .

It remains to be determined whether the endothelial dysfunction and injury seen in COVID-19 predominantly reflects direct infection of EC by SARS-CoV-2 or indirect bystander injury by factors including cytokines, leukocytes, neutrophil nets and complement activation 75 . Notwithstanding, an important consideration is the effect of current cardiovascular drugs in this setting ( Figure 2 ). On the one hand, they may offer enhanced endothelial protection, while on the other they may increase endothelial susceptibility. To date there are only retrospective data to rely upon and prospective clinical studies in COVID-19 with clearly defined cardiovascular endpoints are required. Drugs including HMG-CoA reductase inhibitors (statins), alpha and beta adrenergic blockers and renin-angiotensin-aldosterone system antagonists are widely prescribed in those with diabetes mellitus, hypertension and coronary artery disease, groups known to be at the highest risk from COVID-19. Understanding how these drugs influence outcomes is therefore essential.

In pre-clinical studies, statins increase expression of ACE2. However, these in disease models this may reflect a return to normal levels. Moreover, enhanced expression of ACE2 has cardiovascular benefit 76 . Previously observed beneficial effects in influenza and actions of statins including their ability to reduce CD147 expression, optimise lipid raft function, regulate autophagy, minimise endothelial activation, down-regulate pro-thrombotic pathways and enhance anti-thrombotic effects, alongside immunomodulatory actions, suggest that statins may exert important endothelial protective effects both against and during SARS-CoV-2 infection [77] [78] [79] . COVID-19 clinical trials incorporating statins (NCT04333407; NCT04348695:NCT04380402) have commenced and the results are awaited with interest.

Reported beneficial effects of beta-adrenergic blockers in ARDS and respiratory failure, alongside a potential ability to reduce viral entry by downregulating ACE2 has resulted in these drugs being suggested as an adjunct therapy for COVID-19, even in those without a primary indication 80 .

Retrospective studies underway will help inform this hypothesis. An intriguing large, retrospective analysis of alpha-1 adrenergic receptor antagonists in patients suffering from ARDS or pneumonia has revealed that those incidentally prescribed alpha-blockers were less likely to require ventilation or to die following onset of ventilator support. In contrast, beta-adrenergic blockers had no effect. The clinical study was inspired by pre-clinical data, which demonstrated that alpha-blockade can prevent the ARDS-associated cytokine storm and death in mice by interfering with a catecholamine loop 81 . These findings suggest that alpha-1 adrenergic receptor antagonists merit retrospective and prospective analysis in COVID-19. The identification of the SARS-CoV-2-associated cytokine storm as a potential therapeutic target is also supported by the early data from the dexamethasone arm of the COVID-19 RECOVERY trial 82 .

The ability of SARS-CoV-2 to utilise ACE2 as a co-receptor for cellular entry has led to significant interest in the impact of angiotensin-converting enzyme inhibitors ACE-i and ARBs. Similarly to statins, these commonly used drugs enhance ACE2 76 . Although clinical data are sparse, ACEi and ARBs are reported to improve outcomes in ARDS 83 . There has also been speculation that a dysfunctional RAAS is important for COVID-19 disease pathogenesis 84 . Initial concern regarding potential susceptibility to SARS-CoV-2 infection and/or exacerbation of its effects in those taking ACEi or ARBs have been allayed by retrospective clinical studies [85] [86] [87] . Current advice is to continue taking these drugs prescribed for hypertension, cardiac failure and chronic renal disease, and for physicians to prescribe them for new clinical indications as normal 84 . Prospective studies and clinical trials are now urgently needed. Two clinical trials will study the impact of losartan on COVID-19 (NCT04311177 and NCT04312009). Interest will also focus upon Ang 1-7 peptides, ACE2 itself 76, 84 and monoclonal antibodies that prevent SARS-CoV-2 binding ACE2 88 .

Further research is urgently needed to combat the COVID-19 pandemic and we emphasize that the role of vascular endothelium requires close scrutiny. There are today several outstanding questions that need to be addressed to elucidate more precisely the role of EC in COVID-19 and to investigate potential routes to clinical translation. 5. The long-term cardiovascular effects following recovery from COVID-19 must be determined during planned patient follow up so that appropriate preventive measures can be taken in time if needed. Measuring endothelial function in addition to myocardial injury and respiratory function markers in convalescent patients may represent a possible means for early detection of vascular sequelae post COVID-19.

None declared.

PCE and MB conceived and designed the manuscript, drafted the manuscript and revised it for important intellectual content. GER, JCM, TJG, EO, ZS, DN, IEH, MF, JW, CW, M-L B-P made substantial contributions to the conception and design of the manuscript, and drafted the manuscript or revised it for important intellectual content. All authors approved the final version of the manuscript and agreed to be accountable for the work. Healthy endothelium (left) is characterised by quiescence, intact junctions, anti-coagulant anti-inflammatory phenotype and an intact vasodilation phenotype. The cell in the centre (endothelitis) is infected with SARS-CoV-2, whereas the cells to the right have been activated as a result of cytokine release and activation of pro-thrombotic pathways. Infection with SARS-CoV-2 is via ACE2 which is subsequently endocytosed, potentially reducing ACE2-mediated regulation of vascular tone. SARS-CoV-2 infection causes endothelial dysfunction at multiple levels including inflammatory activation, cytokine storm, leukocyte infiltration, increased permeability, thrombosis, platelet aggregation, vasoconstriction, ROS production and apoptosis.

Endothelial infection with SARS-CoV-2 infection causes dysregulation of the RAAS, apoptosis, thrombosis and inflammation (red tones). Several interventions (green tones) can reduce endothelial dysfunction in COVID-19 including modulators of the RAAS (ACE-i, ARBs, ACE2); anti-inflammatory molecules (cytokine inhibitors, dexamethasone, statins); inhibitors of ROS/apoptosis (statins); platelet inhibitors and anti-coagulants. A healthy lifestyle may also reduce endothelial dysfunction in patients with COVID-19.

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic

ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes

Typical takotsubo syndrome triggered by SARS-CoV-2 infection

Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms

Prognostic value of NT-proBNP in patients with severe COVID-19

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Lip GYH. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Characteristics of ischaemic stroke associated with COVID-19

McInnes IB. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Endothelial cell infection and endotheliitis in COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction

SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases

Endothelial-mesenchymal transition in atherosclerosis

Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes

Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review

Hallmarks of Endothelial Cell Metabolism in Health and Disease

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease

Thrombotic Regulation From the Endothelial Cell Perspectives

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Cytokine storm and sepsis disease pathogenesis

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Endothelial Cells Are Central Orchestrators of Cytokine Amplification during Influenza Virus Infection

Animal Model of Respiratory Syncytial Virus: CD8(+) T Cells Cause a Cytokine Storm That Is Chemically Tractable by Sphingosine-1-Phosphate 1 Receptor Agonist Therapy

Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus

Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality

Sinai Immunology Review P. Advancing scientific knowledge in times of pandemics

Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection

T cell responses to whole SARS coronavirus in humans

COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis

Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells

Cellular pathology of atherosclerosis: smooth muscle cells promote adhesion of platelets to cocultured endothelial cells

Endothelial cell-borne platelet bridges selectively recruit monocytes in human and mouse models of vascular inflammation

Ex vivo modelling of the formation of inflammatory platelet-leucocyte aggregates and their adhesion on endothelial cells, an early event in sepsis

Appropriation of GPlb alpha from platelet-derived extracellular vesicles supports monocyte recruitment in systemic inflammation

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory medicine 2020

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis

Nitrosylation. the prototypic redox-based signaling mechanism

Multiorgan and Renal Tropism of SARS-CoV-2

Electron microscopy of SARS-CoV-2: a challenging task

Curative anticoagulation prevents endothelial lesion in COVID-19 patients

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Hyperinflammatory shock in children during COVID-19 pandemic

Association between a novel human coronavirus and Kawasaki disease

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

What is a pericyte

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Pericytespecific vascular expression of SARS-CoV-2 receptor ACE2 -implications for microvascular inflammation and hypercoagulopathy in COVID-19 patients

Pericyte alteration sheds light on micro-vasculopathy in COVID-19 infection

Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall

Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease

COVID-19, ACE2, and the cardiovascular consequences

Statins: Could an old friend help the fight against COVID-19?

Statin therapy in COVID-19 infection: much more than a single pathway

Statin therapy in COVID-19 infection

Can beta-adrenergic blockers be used in the treatment of COVID-19?

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Action obotE-CC. Call to action for the cardiovascular side of COVID-19: A call for cooperative action from the EU-CardioRNA COST Action